Scientists working for Novartis have taken a step forward in better understanding how new classes of biological drugs might affect patients’ immune systems. Paul Wassmann, PhD senior principal ...

This is an observer-blinded, three-arms study in 376 patients in Chinese individuals aged from 18 to 55 years old who had previously received three doses COVID-19 vaccine. Immunogenicity in terms of ...

As biologics and biosimilars continue to reshape oncology, ensuring their safety and efficacy remains a top priority. In this expert-driven report, Cerba Research examines the latest advancements in ...

Background: This study (NCT00383123) compared the immunogenicity and safety of 2 trivalent inactivated influenza vaccines: Fluarix [GlaxoSmithKline (study vaccine)] and Fluzone [Sanofi Pasteur ...

In the twentieth century, the development and delivery of vaccines as part of large, systematic immunization programs helped to address many health inequities. However, safety concerns due to ...

Antibody humanization involves modifying antibodies from non-human sources, such as mice, to decrease their immunogenicity in human applications. While mouse monoclonal antibodies are specific, they ...

V-212 was well tolerated. Adverse events were predominantly mild to moderate in intensity, with a trend for increasing incidence of systemic reactogenicity with increasing dose level. The incidence of ...

Overall, the study authors concluded that the immunogenicity of quadrivalent influenza vaccines (QIV) and trivalent inactivated influenza vaccines (TIV) was similar for common influenza ingredients ...